image
desktop banner image
image_mobile
Image_disclaimer
Not actual patients.
eyebrow
headline

About LORBRENA® (lorlatinib)

headline2
content
buttons
icon
headline

What is LORBRENA?

subheadline
content
LORBRENA is a once-daily oral prescription medicine (that can be taken with or without food) for adults with anaplastic lymphoma kinase–positive (ALK+) non–small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic).
disclaimer
buttons
eyebrow
headline

How LORBRENA works

headline2
content
LORBRENA is designed to target cancer cells with changes in the ALK gene. It is a type of therapy known as an ALK inhibitor. By blocking or “inhibiting” ALK, LORBRENA helps slow or stop the growth of mNSCLC, including in the brain.
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
icon
headline

How LORBRENA works in the brain

content
The brain is one of the most common places where ALK+ mNSCLC can spread. LORBRENA was specifically designed to cross the blood-brain barrier* and has been shown to help shrink ALK+ NSCLC tumors that have spread to the brain.
disclaimer
*The blood-brain barrier is a network of blood vessels and tissue that protects the brain from harmful substances like bacteria. Treating cancer that has spread to the brain can be difficult because medicines must be able to cross this barrier.
Buttons
image
Grace, patient taking LORBRENA
Mobile_image
Grace, patient taking LORBRENA
eyebrow
headline

“My doctor told me LORBRENA was a first-line treatment that was different than chemotherapy and radiation . . . [We] continued to discuss treatment options, and we decided to give LORBRENA a try.”

subheadline
content
–Grace, patient taking LORBRENA
buttons
Watch her story
content2
disclaimer
Image_disclaimer
Patient was compensated for her time.
Brightcove_video_id
Brightcove_account_id
eyebrow
headline

Clinical trial results

content
disclaimer
eyebrow
headline

Living longer without your ALK+ NSCLC further growing or spreading may be possible with LORBRENA (compared to crizotinib).

headline2
content
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
eyebrow
headline

LORBRENA clinical trial in newly diagnosed patients

headline2
content
LORBRENA is being studied in a clinical trial for people newly diagnosed with ALK+ mNSCLC. In the study, 296 patients were randomly split into 2 groups and given either LORBRENA or crizotinib. Crizotinib is a different medicine for ALK+ NSCLC.
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
image
graph-img
image_mobile
Image_disclaimer
eyebrow
headline
headline2
content
  • At enrollment, all patients were newly diagnosed with ALK+ mNSCLC and had not received any previous treatment for mNSCLC
  • The study included patients with and without cancer that had spread to their brain
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
eyebrow
headline

Progression-free survival

headline2
content

The main goal of the trial is to measure progression-free survival (PFS), which is how long patients live without their tumors growing or spreading (“progressing”). Median* progression-free survival (median PFS) is a measurement taken when half of the patients still taking LORBRENA have had their tumors grow or spread.

The study was designed to measure median PFS at 18 months, but at that point, more than half of the patients on LORBRENA still had not experienced cancer progression. Patients taking crizotinib experienced cancer progression at a median of 9 months.

content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
*The median is the middle value in a set of numbers.
image
graph-img
image_mobile
Image_disclaimer
image
graph-img
image_mobile
Image_disclaimer
eyebrow
headline
headline2
content

LORBRENA was approved for newly diagnosed patients based on the results of the study at 18 months. Because the median PFS had not been reached (more than half of the patients on LORBRENA had not yet experienced cancer progression), patients in the study are still being monitored, and more information is being collected.

Another goal of the study is to measure overall survival, which is the total time patients live from the start of treatment. Data are still being collected, so more time is needed to find out if patients taking LORBRENA live longer than patients taking crizotinib.

content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer

Subheader

How tumors responded to treatment

The analysis at a median of 18 months of follow-up also measured overall response rate, which is tumor response to treatment, including tumor shrinkage and disappearance throughout the body, including the brain.

Results in patients with brain tumors

At the start of the study, 30 patients had brain tumors that could be seen and measured. Of those patients, 17 were treated with LORBRENA and 13 were treated with crizotinib.

7-year follow-up analysis

The patients in the clinical trial are still being monitored, and data are being collected and evaluated. A follow-up analysis was done at a median* of 7 years, once more data were available.

*The median is the middle value in a set of numbers.

The informal analysis was not designed to find specific differences between LORBRENA and crizotinib. Unlike the main analysis, the data did not undergo an additional independent review, and it was not used to support the FDA approval of LORBRENA. The scientists, medical professionals, and investigators assessed the informal analysis at 7 years of follow-up data. The following were observed:

No new safety concerns were detected in the follow-up analysis. The side effects experienced by patients in the main analysis were similar to those experienced in the follow-up analysis at a median of 7 years.

Click for information on potential side effects

eyebrow
headline

LORBRENA clinical trial in newly diagnosed patients

headline2
content
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
image
image_mobile
Image_disclaimer
eyebrow
headline

Results in all patients

headline2
content
In this trial, the overall response rate* was measured, and nearly half of patients had their tumors shrink or disappear with LORBRENA.
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
*Overall response rate measures tumor response to treatment, including tumor shrinkage and disappearance throughout the body, including the brain.
image
image_mobile
Image_disclaimer
eyebrow
headline
headline2
content
These responses lasted for a median* of 13 months.
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
eyebrow
headline

Results in patients with brain tumors

headline2
content
A smaller group of 89 patients had measurable brain tumors† that were no longer responding to certain other medicines for ALK+ NSCLC.
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
image
image_mobile
Image_disclaimer
eyebrow
headline
headline2
content
These responses lasted for a median* of 20 months.
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer

*The median is the middle value in a set of numbers.

†Of the 215 patients in the trial, 148 (69%) had brain tumors at the start of treatment. Eighty-nine of the 148 patients had brain tumors that could be measured.

headline

Considering LORBRENA?

headline2
content
It’s important to feel confident in your treatment decisions. Download the Conversation Guide and talk with your doctor about whether LORBRENA could be right for you. Bring it to your appointments to take notes on what you discuss.
eyebrow
disclaimer
card_identifier
heading

Learn more about treatment with LORBRENA

body
cta
What to expect
card_identifier
heading

Get resources to support your treatment with LORBRENA

body
cta
Sign up
card_identifier
pot logo
Mobile_image
pot logo
heading
body

Turn to Pfizer Oncology Together for financial assistance resources and personalized support.

Call 1-877-744-5675 (Monday-Friday 8 AM-8 PM ET)

cta
Visit PfizerOncologyTogether.com